Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : wla(warner lambert) -- Ignore unavailable to you. Want to Upgrade?

To: Zoltan! who wrote (111)	12/1/1997 5:42:00 PM
From: Sonki	Read Replies (2) \| Respond to of 942

duncan ...hi ! i m thinking of jumping into wla tomorrow. do u think this is too much overreaction to one drug? earnings revised downwards by 8%. though pe is still hi. what do u think?

To: Zoltan! who wrote (111)	12/1/1997 5:54:00 PM
From: Alec Epting	Read Replies (1) \| Respond to of 942

Phase II? Sounds like it will be a while before the drug is approved.

To: Zoltan! who wrote (111)	12/1/1997 7:27:00 PM
From: Ted Downs	Read Replies (1) \| Respond to of 942

Duncan, << Either way, Glaxo stands to be the big winner. >> You don't think the fact that Glaxo has their competing drug in trials would in any way affect their judgement to pull WLA's drug rather quickly? Apparently there are other people pondering the question including Goldman Sachs analyst Prem Lachman. "Goldman Sachs' Lachman, though, said Glaxo Wellcome is developing its own glitazone drug,which is entering interim-stage trials and may have played a role in the company's decision. "We wonder what their motivation is with respect to the (suspension)," Lachman said. reported on Dow Jones